losartan-potassium has been researched along with Hepatitis-B--Chronic* in 2 studies
1 trial(s) available for losartan-potassium and Hepatitis-B--Chronic
| Article | Year |
|---|---|
Influence of IFN-alpha on plasma erythropoietin levels in patients with hepatitis B virus-associated chronic active hepatitis.
The influence of 3-month interferon-alpha (IFN-alpha) treatment on plasma erythropoietin (EPO) concentration in patients with chronic active hepatitis (CAH) induced by hepatitis B virus (HBV) infection was investigated. The study was carried out in 44 nonanemic patients divided into two groups: CAH B, 30 subjects not treated with IFN-alpha, and CAH B-IFN, 14 subjects treated with IFN-alpha for the first 3 months of the study (5 MU/m(2) body surface subcutaneously (s.c.) three times per week). In all patients, blood samples were taken at the beginning of the study (0) and after 1, 2, 3, 6, 9, and 12 months of observation. At the beginning, plasma EPO levels in the CAH B (27.8 +/- 2.21 mU/ml) and CAH B-IFN (27.3 +/- 3.04 mU/ml) groups did not differ significantly from each other and were significantly higher (p < 0.0001) than in healthy subjects (10.4 +/- 1.06 mU/ml). In patients in the CAH B group, plasma EPO concentrations did not change significantly during the whole observation period. In patients in the CAH B-IFN group, a transient, significant increase in plasma EPO level was found. The highest plasma EPO concentration in this group was noted after the third month of treatment (41.1 +/- 3.41 mU/ml). In conclusion, patients with CAH induced by HBV infection are characterized by increased plasma EPO concentrations, and IFN-alpha treatment in these patients causes a transient increase in the plasma EPO level. Topics: Adult; Alanine Transaminase; Erythropoietin; Female; Hepatitis B, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Male; Up-Regulation | 2001 |
1 other study(ies) available for losartan-potassium and Hepatitis-B--Chronic
| Article | Year |
|---|---|
Chronic hepatitis ameliorates anaemia in haemodialysis patients.
Study for influence of chronic hepatitis (CH) on anaemia in haemodialysis (HD) patients remains inconclusive. We aim to characterize the red cell status between CH and hepatitis-free groups among the HD population.. We retrospectively analysed 80 chronic HD patients from Taipei Medical University Hospital with monthly sampled biochemical study between December 2004 and December 2005. Data classified according to the hepatitis-free, chronic hepatitis B and C groups were expressed as mean +/- standard deviation. Student's t-test and anova were used to determine the mean difference for continuous variables.. Age, Kt/V, systolic or diastolic blood pressure, body mass index, total cholesterol and triglyceride were not different between CH and hepatitis-free groups. HD duration (P = 0.0002), aspartate (P < 0.0001), alanine aminotransferase (P < 0.0001), alkaline phosphatase (P = 0.04), haemoglobin (P = 0.0066) and haematocrit (P = 0.002) were significantly more elevated in the CH group demanding less erythropoietin dose than in the hepatitis-free group.. Our study demonstrated that lessened anaemia was observed in CH, which demanded less erythropoietin dose. Topics: Aged; Alanine Transaminase; Anemia; Aspartate Aminotransferases; Erythropoietin; Female; Hematinics; Hematocrit; Hemoglobins; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Injections, Intravenous; Kidney Diseases; Male; Middle Aged; Recombinant Proteins; Renal Dialysis; Retrospective Studies | 2008 |